Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy

Sponsor
Harvard School of Public Health (HSPH) (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03350516
Collaborator
St. John's Research Institute (Other), Ifakara Health Institute (Other), Africa Academy for Public Health (Other)
22,000
3
2
48
7333.3
152.7

Study Details

Study Description

Brief Summary

The World Health Organization currently recommends that pregnant women in populations with low calcium intake receive daily calcium supplementation (1500 - 2000 mg) divided into three doses which are preferably taken at mealtimes, in addition to daily iron folic-acid supplements. Despite proven efficacy and the WHO recommendation, calcium supplementation in pregnancy is not standard of care in the vast majority of low-income and middle-income countries. Two important barriers to implementation are the cost of the supplements and complexity of the suggested calcium dosing schedule. A lower dose of calcium (500 mg) administered as a single dose has been shown to be beneficial in several trials, and if found to be as effective as the 1500 mg supplementation regimen, it may help overcome these barriers and increase individual and health system adoption.

The Investigators will conduct two parallel, individually randomized, double blind non-inferiority trials in India and Tanzania. Participating pregnant woman will be randomized to either 1500 mg or 500 mg calcium supplementation. The India and Tanzania trials are independently powered for the primary outcomes of i) preeclampsia and ii) preterm birth. The India and Tanzania sites will each enroll 11,000 participants.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Daily 500 mg elemental calcium as calcium carbonate
  • Dietary Supplement: Daily1500 mg elemental calcium as calcium carbonate
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
22000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Demonstrating Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy for Reducing Preeclampsia and Neonatal Outcomes
Actual Study Start Date :
Nov 30, 2018
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Daily 500 mg Calcium

Dietary Supplement: Daily 500 mg elemental calcium as calcium carbonate
Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.

Active Comparator: Daily1500 mg Calcium (Standard dose)

Dietary Supplement: Daily1500 mg elemental calcium as calcium carbonate
Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.

Outcome Measures

Primary Outcome Measures

  1. Proportion of pregnant women with incident preeclampsia [Gestational week 20 to Delivery]

  2. Proportion of preterm birth [Birth]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Nulliparous

  • Attending first ANC visit at study clinics

  • Pregnant women <20 weeks

  • ≥ 18 years old

  • Intending to stay in study area until 6 weeks post delivery

  • Provides informed consent

Exclusion Criteria:
  • History or signs and/or symptoms of nephrolithiasis

  • Prior diagnosis of parathyroid disorder or thyroidectomy

  • Diseases that require digoxin, phenytoin, or tetracycline therapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 St. John's Research Institute Bangalore India
2 Africa Academy for Public Health Dar Es Salaam Tanzania
3 Ifakara Health Institute Dar Es Salaam Tanzania

Sponsors and Collaborators

  • Harvard School of Public Health (HSPH)
  • St. John's Research Institute
  • Ifakara Health Institute
  • Africa Academy for Public Health

Investigators

  • Principal Investigator: Wafaie W Fawzi, MBBS, DrPH, Harvard School of Public Health (HSPH)

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wafaie Fawzi, Richard Saltonstall Professor of Population Sciences, Professor of Nutrition, Epidemiology, and Global Health, Chair of the Department of Global Health and Population, Harvard School of Public Health (HSPH)
ClinicalTrials.gov Identifier:
NCT03350516
Other Study ID Numbers:
  • OPP1172660
First Posted:
Nov 22, 2017
Last Update Posted:
Mar 16, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 16, 2022